Stock RA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Ra Pharmaceuticals, Inc.

Equities

US74933V1089

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ra Pharmaceuticals, Inc.(NasdaqGM:RARX) dropped from S&P TMI Index
CI
Ra Pharmaceuticals, Inc.(NasdaqGM:RARX) dropped from S&P Global BMI Index
CI
Ra Pharmaceuticals, Inc.(NasdaqGM:RARX) dropped from S&P Biotechnology Select Industry Index
CI
RA PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
UCB SA completed the acquisition of Ra Pharmaceuticals, Inc. from Douglas A. Treco, New Enterprise Associates 13, L.P. managed by New Enterprise Associates and RA Capital Healthcare Fund, L.P managed by Ra Capital Management, LLC and others.
CI
RA PHARMACEUTICALS, INC. : Other Events (form 8-K)
AQ
RA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
Ra Pharmaceuticals : Supports 13th Annual Rare Disease Day and Joins Global Movement to Raise Awareness for Rare Diseases
AQ
RA PHARMACEUTICALS, INC. : Other Events (form 8-K)
AQ
Ra Pharmaceuticals : Supports 13th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases
BU
Ra Pharmaceuticals : Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
BU
Ra Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019
CI
RA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
Ra Pharmaceuticals : Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology
BU
Ra Pharmaceuticals, Inc. Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology
CI
Ra Pharmaceuticals : Announces Clearance of IND Application for the HEALEY ALS Platform Trial
BU
Ra Pharmaceuticals, Inc. Announces Clearance of IND Application for the HEALEY ALS Platform Trial
CI
RA PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)
AQ
Ra Pharmaceuticals : Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM
BU
Ra Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Ra Pharmaceuticals, Inc.